Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Valerio Therapeutics
Valerio Therapeutics
Dartmouth-Hitchcock Medical Center
Case Comprehensive Cancer Center